Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Johnson & Johnson (JNJ) is a leading drug manufacturers-general business based in the US. It opened the day at $168.63 after a previous close of $168.76. During the day the price has varied from a low of $167.15 to a high of $168.65. The latest price was $167.84 (25 minute delay). Johnson-and-Johnson is listed on the NYSE and employs 134,500 staff. All prices are listed in US Dollars.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Open | $168.63 |
|---|---|
| High | $168.65 |
| Low | $167.15 |
| Close | $167.84 |
| Previous close | $168.76 |
| Change | $-0.92 |
| Change % | -0.5452% |
| Volume | 5,847,839 |
| 52-week range | $148.67 - $177.77 |
|---|---|
| 50-day moving average | $166.02 |
| 200-day moving average | $166.87 |
| Wall St. target price | $186.44 |
| PE ratio | 25.0844 |
| Dividend yield | $4.14 (2.53%) |
| Earnings per share (TTM) | $6.69 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $167.84 from 2022-01-20
| 1 week (2022-01-14) | 167.84 |
|---|---|
| 1 month (2021-12-17) | N/A |
| 3 months (2021-10-21) | 2.72% |
| 6 months (2021-07-21) | -0.97% |
| 1 year (2021-01-21) | 3.78% |
|---|---|
| 2 years (2020-01-21) | 12.44% |
| 3 years (2019-01-18) | 28.43% |
| 5 years (2017-01-20) | 47.03% |
Valuing Johnson-and-Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson-and-Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Johnson-and-Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Johnson-and-Johnson shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Johnson-and-Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.622. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson-and-Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Johnson-and-Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $31.5 billion.
The EBITDA is a measure of a Johnson-and-Johnson's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $91.4 billion |
|---|---|
| Operating margin TTM | 26.29% |
| Gross profit TTM | $54.3 billion |
| Return on assets TTM | 8.59% |
| Return on equity TTM | 26.54% |
| Profit margin | 19.55% |
| Book value | $26.69 |
| Market capitalisation | $441.9 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson-and-Johnson.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 35.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson-and-Johnson's overall score of 35.8 (as at 12/31/2018) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Johnson-and-Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.79/100
Johnson-and-Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 25.14/100
Johnson-and-Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 14.87/100
Johnson-and-Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson-and-Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson-and-Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson-and-Johnson has a damaged public profile.
Johnson & Johnson was last rated for ESG on: 2019-01-01.
| Total ESG score | 35.8 |
|---|---|
| Total ESG percentile | 72.38 |
| Environmental score | 3.79 |
| Environmental score percentile | 7 |
| Social score | 25.14 |
| Social score percentile | 7 |
| Governance score | 14.87 |
| Governance score percentile | 7 |
| Level of controversy | 4 |
Dividend payout ratio: 43.97% of net profits
Recently Johnson-and-Johnson has paid out, on average, around 43.97% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.53% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson-and-Johnson shareholders could enjoy a 2.53% return on their shares, in the form of dividend payments. In Johnson-and-Johnson's case, that would currently equate to about $4.14 per share.
While Johnson-and-Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson-and-Johnson may be investing much of the rest of its net profits in future growth.
Johnson-and-Johnson's most recent dividend payout was on 7 March 2022. The latest dividend was paid out to all shareholders who bought their shares by 17 February 2022 (the "ex-dividend date").
Johnson-and-Johnson's shares were split on a 2:1 basis on 12 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson-and-Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson-and-Johnson shares which in turn could have impacted Johnson-and-Johnson's share price.
Over the last 12 months, Johnson-and-Johnson's shares have ranged in value from as little as $148.6678 up to $177.7656. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson-and-Johnson's is 0.7364. This would suggest that Johnson-and-Johnson's shares are less volatile than average (for this exchange).
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o. b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.